Schmid HP - Search Results

1

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A. Cuzick J, et al. Among authors: schmid hp. Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Lancet Oncol. 2014. PMID: 25281467 Free PMC article. Review.

2

[Natural follow-up of prostate cancer and consequences for early detection].

Schmid HP. Schmid HP. Schweiz Rundsch Med Prax. 1993 Nov 2;82(44):1239-43. Schweiz Rundsch Med Prax. 1993. PMID: 7505945 German.

3

[Long-term follow-up of serum prostate-specific antigen after radiotherapy of prostatic carcinoma].

Schmid HP, Ferrari MK, Stamey TA. Schmid HP, et al. Helv Chir Acta. 1994 Dec;60(6):1101-5. Helv Chir Acta. 1994. PMID: 7533148 German.

4

Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.

Schmid HP. Schmid HP. Cancer Surv. 1995;23:157-67. Cancer Surv. 1995. PMID: 7542562

5

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.

Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Stamey TA, et al. Among authors: schmid hp. Cancer. 1993 Feb 1;71(3 Suppl):933-8. doi: 10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l. Cancer. 1993. PMID: 7679045

6

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume.

Schmid HP, McNeal JE, Stamey TA. Schmid HP, et al. Cancer. 1993 Mar 15;71(6):2031-40. doi: 10.1002/1097-0142(19930315)71:6<2031::aid-cncr2820710618>3.0.co;2-q. Cancer. 1993. PMID: 7680277

7

Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.

Schmid HP, Ravery V, Billebaud T, Toublanc M, Boccon-Gibod LA, Hermieu JF, Delmas V, Boccon-Gibod L. Schmid HP, et al. Urology. 1996 May;47(5):699-703. doi: 10.1016/s0090-4295(96)00018-0. Urology. 1996. PMID: 8650868 Clinical Trial.

8

[Detection of prostatic cancer in symptomatic patients with serum levels of prostate-specific antigen between 4 and 10 ng/ml].

Ravery V, Schmid HP, Billebaud T, Toublanc M, Boccon-Gibod L, Hermieu JF, Delmas V, Boccon-Gibod L. Ravery V, et al. Among authors: schmid hp. Presse Med. 1996 Feb 24;25(7):272-6. Presse Med. 1996. PMID: 8685164 French.

9

A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer.

Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A. Oberpenning F, et al. Among authors: schmid hp. Clin Chem Lab Med. 2003 Jan;41(1):90-4. doi: 10.1515/CCLM.2003.016. Clin Chem Lab Med. 2003. PMID: 12636056 Free article.

10

Problems with prostate-specific antigen screening: a critical review.

Schmid HP, Prikler L, Semjonow A. Schmid HP, et al. Recent Results Cancer Res. 2003;163:226-31; discussion 264-6. doi: 10.1007/978-3-642-55647-0_20. Recent Results Cancer Res. 2003. PMID: 12903857 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

305 results

Search Page